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Abstract
Extracorporeal membrane oxygenation (ECMO) has emerged as an invaluable tool for
bridging severe isolated or combined failure of lung and heart. Due to massive technical
improvements, the application of ECMO is growing fast. While historically ECMO was
initiated and maintained by cardiac surgeons, in recent times interventional cardiolo‐
gists and intensive care specialists increasingly run ECMO systems independently with
great success. Percutaneous ECMO circuits are usually set up in a dual cannulation
mode,  either  as  veno-venous  or  as  veno-arterial  configuration.  A  novel  advanced
strategy is the cannulation of three large vessels (triple cannulation), resulting in veno-
veno-arterial or veno-arterio-venous cannulation. Both veno-venous and veno-arterio-
venous cannulation may further be upgraded to veno-pulmonary-arterial  or veno-
arterial-pulmonary arterial cannulation, respectively. Triple cannulation expands the
field of ECMO application but substantially increases the complexity of ECMO circuits.
In this chapter, we review percutaneous dual and triple cannulation strategies, featuring
a recently proposed unifying nomenclature. This unequivocal code universally applies
to both dual and triple cannulation strategies (VV, VPa, VA, VVA, VAV, VAPa). The
technical  evolution  of  ECMO is  growing fast,  but  it  has  to  be  noted that  current
knowledge of ECMO support is mainly based on observation. Thus controlled trials are
urgently needed to prospectively evaluate different ECMO modes.
Keywords: cardiogenic shock, heart failure, ECMO, extracorporeal circulation, me‐
chanical circulatory support, triple cannulation
1. Introduction
In 1972, the first report of successful extracorporeal membrane oxygenation (ECMO) was
published [1]. Since then extracorporeal membrane oxygenation (ECMO) has emerged as a
central method for supporting acute severe heart and lung failure. The current broad use of
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ECMO was made possible by many technical improvements of tubings, surfaces, oxygena‐
tors, and other parts of the circuit. Recently, randomized and observational studies have
demonstrated that the so far widely used intra-aortic balloon pumps are not as beneficial as
expected in patients with shock [2, 3]. Thus, the frequency of use of ECMO will likely further
increase in the future.
Strategy Indication
(example)
Principle Exit Reference
Bridge to
recovery
Myocarditis Replacement of organ function
until recovery allows weaning of
ECMO
ECMO removal Asaumi et al. [29],
Lorusso et al. [30]
ARDS Preoxygenation of venous blood
to allow for lung-protective
ventilator settings and pulmonary
recovery
ECMO removal Hoeper et al. [18]
Bridge to
transplantation
Respiratory failure
from lung disease
without prospect of
recovery
Replacement of organ function
until transplantation of the failing
organ
Transplantation Fuehner et al. [15]
Schmidt et al. [17]
Bridge to
destination
Terminal heart
failure
Replacement of organ function
until implantation of a permanent
assist device
LVAD surgery Haneya et al. [38]
Bridge to
decision
Resuscitation Replacement of organ function
with the intention to gain time
until decision on the final strategy
can be made
Improve end organ
function, assess
neurological outcome on
ECMO support, to
evaluate the patient for a
reasonable exit strategy
(e.g., potential LVAD
implantation)
Rousse et al. [39]
Interhospital
transfer of patients
with ARDS or
cardiogenic shock,
refractory to
medical therapy
ECMO implantation in the
peripheral hospital, transfer of
stabilized patient to tertiary
cardiovascular center
Improve end organ
function and complete
diagnostics to determine
exit strategy (recovery vs.
permanent assist device)
Javidfar et al. [35]
ARDS, acute respiratory distress syndrome; LVAD, left ventricular assist device.
Table 1. Strategies of ECMO support for heart and/or lung failure.
The most common ECMO configuration is “dual-cannulation,” i.e., veno-venous (VV) or veno-
arterial (VA) cannulation with two large-bore cannulae. VV-ECMO drains desaturated blood
from the right atrium and returns it after oxygenation and decarboxylation again to the right
atrium. By this, it works like an extracorporeal lung and is classically used in patients with
severe acute respiratory distress syndrome (ARDS). In contrast, VA-ECMO drains blood from
the right atrium and returns it after passing the ECMO device to the patient’s arterial system,
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usually via the femoral artery toward the aorta. By this, VA-ECMO generates a large extrac‐
orporeal right-to-left shunt and primarily provides hemodynamic support, whereas the effect
on oxygenation depends on several factors such as cannulation sites, the patient’s cardiac
output, and respiratory function. Thus, considering the profound effects on hemodynamics
and gas exchange, VA-ECMO is essentially different from VV-ECMO, and each has its own
indications.
Regardless of the cannulation mode, ECMO can be used with different strategies (Table 1):
bridge-to-recovery, bridge-to-transplantation, bridge-to-destination, or bridge-to-decision.
However, notwithstanding today’s very quick setup of the system due to major technical
improvements, ECMO is an invasive life support system potentially leading to vascular
complications, bleeding, thromboembolic events, and infection [4]. ECMO support can be
easily initiated, but its termination in a bridge-to-recovery strategy requires careful weaning.
Therefore, an experienced team of cardiologists, cardiac surgeons and intensive care specialists
(and pulmonologists on the case of lung failure) should evaluate every patient before ECMO
initiation, in order to reach consensus on the individualized therapeutic concept. Guidelines
on indications, use, and weaning from ECMO support in children and adults are available
from the Extracorporeal Life Support Organization (ELSO) [5]. In general and compared to
other invasive therapies, the level of evidence is limited for ECMO. Large prospective trials
are sparse, even if several smaller studies, case series, and registries are available. This is in
part due to the acute lifesaving nature of the device, where the clinical need has passed the
chance to conduct prospective studies.
Table 2. ECMO cannulation modes.
The clinical need has also led to innovative applications for ECMO under special circumstan‐
ces, beyond classical dual cannulation. The novel concept of triple cannulation addresses
inadequate draining during veno-arterial ECMO and combined cardiopulmonary failure on
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either veno-arterial or veno-venous ECMO. As triple cannulation resulted in a confusing use
of multiple abbreviations during clinical routine, we have recently proposed a unifying
terminology of ECMO cannulation modes [6].
In this chapter, we very briefly review the features of dual cannulation ECMO and then
summarize current indications, pathophysiology, and strategies for percutaneous triple
cannulation ECMO support. An overview on cannulation modes is given in Table 2. It should
not remain unmentioned that other extracorporeal systems beyond ECMO are available, but
these are off the focus of this chapter and are described elsewhere [7, 8].
2. Dual cannulation ECMO
Dual cannulation ECMO may be instituted as veno-venous or veno-arterial ECMO. Both are
essentially different in terms of setup, support, and monitoring.
2.1. Veno-venous cannulation (VV)
During VV-ECMO, deoxygenated blood is drained from the right atrium and returned after
extracorporeal reoxygenation and decarboxylation again to the right atrium (Figure 1). ECMO-
derived preoxygenated blood enters the pulmonary circuit and provides systemic oxygena‐
tion, thus allowing for establishing lung-protective respirator settings. The most common
indication for VV-ECMO is ARDS [9–14]. In ARDS, ECMO is considered with a Horovitz index
below 100 to 150 or uncompensated acidosis (pH <7.2) and has already been applied in awake
patients [15–17] or even to fully avoid invasive ventilation [18]. Notwithstanding the need of
prospective controlled trials, VV-ECMO has already entered center stage in severe ARDS in
tertiary centers, which was further promoted by the recent H1N1 wave [19–22]. VV-ECMO
should not be initiated in patients with terminal respiratory failure, when there is no perspec‐
tive of organ recovery or lung transplantation.
VV-ECMO cannulae are usually introduced via the femoral and jugular veins (Figure 1), with
upper-body cannulation by using a bicaval dual lumen cannula [6, 23] only through the right-
sided jugular vein as an elegant alternative. With femoral-jugular cannulation, it is essential
to position the tips of both cannulae at the border between the right atrium and the caval veins
(Figure 1) to minimize recirculation. On VV-ECMO, oxygen saturation in the central aorta
results from a mixture of reoxygenation in the ECMO and remaining gas exchange in the lungs.
Improvement of end organ supply often results in a reduction of vasopressors, but VV-ECMO
does not influence hemodynamics per se, as equal blood volumes are drained from and
supplied to the right atrium (Table 1). Right or left heart failure in patients on VV-ECMO is a
potential indication for triple cannulation (see below), thus echocardiographic monitoring is
very important during support.
Extracorporeal Membrane Oxygenation: Advances in Therapy82
Figure 1. Veno-venous ECMO (VV). VV-ECMO drains venous blood (blue) from the right atrium and the inferior vena
cava and returns an equal volume after reoxygenation and decarboxylation (red) again to the right atrium. PaPmean
denotes the mean pulmonary arterial pressure, LVEDP left-end diastolic pressure, RaP mean right atrial pressure, and
SBP systemic blood pressure. Pressure and medication changes given in the figures are mainly derived from clinical
experience and remain to be validated by dedicated studies. LVEDP denotes left ventricular end diastolic pressure,
PaP pulmonary arterial pressure, RaP right atrial pressure, and SBP systolic blood pressure.
2.2. Veno-pulmonary-arterial cannulation (VPa)
This is a very recent modification of VV-ECMO, which has not been validated in studies und
is just described here for the purpose of completeness. VPa cannulation intends to provide
similar support as VV-ECMO, i.e., to drain venous blood from the right atrium and to supply
reoxygenated and decarboxylated blood back toward the pulmonary circulation. The differ‐
ence to VV-ECMO is that the supplying cannula does not end at the right atrium but is
forwarded through the tricuspid valve, the right ventricle, and the pulmonary valve to the
pulmonary artery (Figure 2). This has to be performed under angiographic (or transesophageal
echocardiographic) guidance, and for this purpose a flexible 17-French cannula is necessary.
Furthermore, the draining cannula tip should be positioned in the mid right atrium to facilitate
homogenous drainage of the upper and lower body.
Triple Cannulation ECMO
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Figure 2. Veno-pulmonary-arterial ECMO (VPa). VPa-ECMO drains venous blood (blue) from the right atrium and re‐
turns an equal volume after reoxygenation and decarboxylation (red) to the pulmonary artery. Note the modified posi‐
tion of the draining venous cannula tip compared to VV-ECMO.
The main advantage of VPa cannulation is the bypass of the right ventricle, which in turn
requires a competent pulmonary valve. As such, this type of cannulation may be used in
patients with isolated right heart failure or with right heart failure while on VV-ECMO support.
Again, it has to be noted that this type of ECMO is novel and has not been validated in clinical
trials. It further requires sufficient left ventricular function, and left heart failure on VPa-ECMO
may be an indication for triple cannulation (see below). In general, isolated right heart failure
may also be bridged by a novel dedicated microaxial right heart assist device (Impella RP®,
Abiomed) [24]. However, in contrast to VPa-ECMO, this approach provides mere hemody‐
namic assistance but no respiratory support by reoxygenation and decarboxylation of venous
blood.
2.3. Veno-arterial cannulation (VA)
The second major indication for ECMO is hemodynamic support in severe heart failure, which
has already been introduced to current guidelines [25]. For hemodynamic support, VA-
cannulation is performed. Here blood is drained from the right atrium similar to VV-ECMO
but returned to a large artery toward the aorta (Figure 3). This institutes an extracorporeal
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right-to-left-shunt in order to reduce preload and to increase aortic blood flow for end organ
perfusion (Figure 3). That leads to the stabilization of blood pressure in most cases, but this
secondary effect depends on vascular resistance and filling. As such, vasopressor dosing and
volume supplementation have to be carefully adjusted during VA-ECMO.
Figure 3. Veno-arterial ECMO (VA). VA-ECMO drains venous blood (blue) from the right atrium and returns an equal
volume after reoxygenation and decarboxylation (red) to the iliac artery toward the aorta. Note the modified position
of the draining venous cannula tip compared to VV-ECMO. Femoral arterial cannulation requires an extra sheath for
antegrade perfusion of the leg (inset).
VA-ECMO has successfully been used in various conditions such as post-cardiotomy cardio‐
genic shock [26], shock caused by myocardial infarction [27], decompensated non-ischemic
heart failure [28], fulminant myocarditis [29, 30], or pulmonary embolism prior to embolecto‐
my [31, 32] in all of the aforementioned cases in a bridge-to-recovery strategy. As with VV-
ECMO, VA-ECMO has successfully been used in awake patients avoiding mechanical
ventilation [33]. VA-ECMO is further used in a bridge-to-transplantation strategy for right
ventricular failure during decompensated pulmonary arterial hypertension before lung
transplantation [34]. Transportable ECMO systems are available for the stabilization of
Triple Cannulation ECMO
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patients with cardiogenic shock in order to transfer them to a tertiary cardiovascular center
[35]. While elective high-risk percutaneous coronary intervention has been successfully
performed under VA-ECMO support [36], a percutaneous microaxial pump (Impella®)
appears to be equally effective with lower procedural risk [37]. VA-ECMO can further be useful
for preconditioning prior to implantation of a permanent left ventricular assist device (LVAD)
in a bridge-to-destination strategy [38]. Regarding donor organ shortage, this approach will be
increasingly important in the future compared to a bridge-to-transplantation strategy. A bridge-
to-decision strategy [39] is followed in patients after resuscitation, with the intention to gain
time, while end organ perfusion is improved until neurological outcome after resuscitation
can be evaluated. The use of VA-ECMO is further beneficial during the early postoperative
phase after lung transplantation, while the heart is not ready to manage reconstituted left
ventricular preload [40]. As in recent years, efforts are made to improve the outcome after out-
of-hospital resuscitation, and VA-ECMO will also play an important role here [41], since
available outcome data suggest a benefit in this context [42, 43]. Notwithstanding the broad
use of VA-ECMO, and promising results from smaller studies, large prospective studies are
missing.
VA-ECMO cannulae are usually introduced via the femoral vein and artery (Figure 3), but the
venous cannula may also drain blood via a jugular vein, especially when VV-ECMO with
existing jugular access is switched to VA-ECMO. In contrast to VV-ECMO, the venous cannula
tip should be placed in the mid right atrium (Figure 3) to enable homogenous drainage of the
upper and lower body. Upper-body cannulation via the jugular vein and subclavian artery is
also possible [6].
Arterial cannulation introduces several important differences to VV-ECMO, which have to be
considered in both VA- and triple cannulation ECMO. One of the most important issues is the
so-called watershed phenomenon, i.e., an artificial competition zone between antegrade blood
flow from the heart and retrograde blood flow from the ECMO [6, 31, 44]. It is located at a
region somewhere between the ascending aorta and the thoracic aorta at the diaphragm level
in most cases, and varies over time [44] and between individual patients. As a result, the upper
body including the brain is perfused with “heart blood” and the lower body with “ECMO
blood.” Accordingly, lung failure during VA-ECMO may result in hypoxic damage to the heart
and brain despite good perfusion pressure, because blood derived from the heart is incom‐
pletely saturated. This condition is a potential indication for triple cannulation ECMO (see
below). Second, femoral arterial cannulation requires an additional sheath to ensure distal
arterial perfusion (Figure 3, inset) [45], and arterial access may lead to substantial vascular
complications [45]. Lastly, left ventricular distension and pulmonary congestion may emerge
after the onset of VA-ECMO support, especially in cases of extremely low left ventricular
output or aortic regurgitation. In such cases, triple cannulation for enhanced venous unloading
can be helpful (see below) [5]. A novel promising solution to compensate for insufficient or
missing antegrade flow across the aortic valve on VA-ECMO support is additional percuta‐
neous left ventricular unloading by a microaxial pump (Impella®, Abiomed), which is
described elsewhere [46–48].
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The aspects described above (watershed, antegrade perfusion sheath, LV distension/pulmo‐
nary edema) have to be considered in all patients on femoral-arterial cannulation, however,
do not apply to central and only in part to subclavian arterial cannulation.
3. Triple cannulation
Triple cannulation ECMO is a novel and complex form of mechanical support. In most cases,
it is instituted by adding a third cannula to an existing VV- or VA-ECMO circuit. The term
“triple cannulation” primarily means the use of three cannulae; however, these may be used
in a veno-veno-arterial (VVA) or veno-arterio-venous (VAV) mode. As VVA and VAV modes
have strongly different effects on circulatory and respiratory support as well as associated
ventilator and medical management, we here describe both configurations separately. In
general, triple cannulation is a promising approach for selected patients, but evidence from
the available literature is limited, and it should be used by experienced centers only.
3.1. Veno-veno-arterial cannulation (VVA)
VVA-ECMO is a special variant of VA-ECMO, in order to improve drainage with a second
venous cannula. In general, VA-ECMO intends to provide hemodynamic support and car‐
diac unloading during severe left-sided, right-sided, or biventricular heart failure. In this
context, filling pressures, i.e., pulmonary arterial and capillary wedge pressures, serve as ro‐
bust markers of VA-ECMO efficacy. However, in some patients, venous drainage is not suf‐
ficient, resulting in either reduced ECMO flow or upper body hypoxemia (also termed
differential hypoxia or two-circulation syndrome) [49, 50]. This may occur by using insuffi‐
cient cannula diameters or in very large patients. Then, the addition of a second draining
cannula aims to improve venous drainage, resulting in triple cannulation (two for drainage
and one for supply, Figure 4).
Unloading by standard VA-ECMO may further be insufficient in special situations, e.g.,
congenital heart defects or coexisting intracardiac shunts and pulmonary arterial hyperten‐
sion. Then intracardiac right-to-left shunt may result in myocardial and cerebral hypoxia. A
third cannula which drains blood from the right atrium or the right ventricle (Figure 4) is often
sufficient to optimize unloading, increase upper body drainage, and reduce intracardiac
shunts. Left ventricular distension during VA-ECMO represents another indication for
enhanced drainage by VVA triple cannulation. Furthermore, in patients with insufficient flow
through the draining cannula or hemolysis due to high flows, VVA may be helpful to enable
high flows and reduce hemolysis [51, 52].
While standard VA-cannulation is often performed on the ward with post-hoc imaging to
verify cannula position, the second venous draining cannula should always be placed under
live imaging, such as fluoroscopy or transesophageal echocardiography. Flows from both
venous cannulae are then merged with a Y-connector outside of the body to return to the
ECMO unit via a single tubing (Figure 4). As VVA ECMO is a special form of VA-ECMO with
enhanced drainage, hemodynamic consequences are comparable to VA cannulation (Figure 4).
Triple Cannulation ECMO
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Figure 4. Veno-veno-arterial ECMO (VVA). VVA-ECMO drains venous blood (blue) via the jugular and femoral vein
from the right atrium and returns all drained blood after reoxygenation and decarboxylation (red) to the iliac artery
toward the aorta. The draining flows from the two venous cannulae are merged by a Y-connector.
VVA-
ECMO
N Description Outcomes
Ford and
Atkinson
1992 [52]
1 Respiratory failure from congenital diaphragmal
hernia in a 3000-g newborn. After 24 h, VA-ECMO
support was insufficient due to limited drainage.
After upgrade to VVA cannulation, central venous
oxygen saturation improved, indicating
improvement of drainage and subsequent supply
Surgery for repair of hernia was
performed, ECMO could be removed after
weaning. The child was discharged home
after 31 days.
Hou et al.
2015 [50]
Sheep
model
Animal study investigating the role of different locations of drainage during ECMO support.
Acute respiratory failure was induced while VA-ECMO with inferior vena cava drainage was
running. Severe upper body hypoxemia developed, with no significant effect on blood
pressure. The venous drainage cannula was repositioned to the superior vena cava, and aortic
oxygen saturation increased from 35 to 75%, by this reverting upper body hypoxemia. This
proof-of-principle study demonstrates that bicaval drainage is sufficient to disrupt “two-
circulation syndrome.”
ELSO [5] Guideline The ELSO guideline for ECMO support in adults describes the option to change VA-
cannulation to VVA-cannulation for improving venous drainage
Table 3. Publications on VVA ECMO support.
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At present, VVA-ECMO has been used in selected cases only (Table 3), and robust study data
do not exist.
3.2. Veno-arterio-venous cannulation (VAV)
This type of triple cannulation is probably one of the most promising steps forward in complex
clinical situations. VAV-ECMO is used in patients with coexisting severe lung and heart
failure. While the drainage cannula draws blood from the right atrium, the ECMO outflow is
divided into two parts: One toward the aorta and one toward the right atrium (Figure 5). As
such, VAV-ECMO represents a mixture of both VV- and VA-ECMO and provides hemody‐
namic and respiratory support at the same time. This approach is sufficient to rescue combined
heart and lung failure in selected cases, such as severe left ventricular failure with secondary
ARDS or right heart decompensation during ARDS.
Figure 5. Veno-arterio-venous ECMO (VAV). VAV-ECMO drains venous blood (blue) from the right atrium and re‐
turns balanced volumes blood after reoxygenation and decarboxylation (red) to the iliac artery toward the aorta and to
the right atrium toward the pulmonary circulation. For this purpose, the ECMO outflow is divided by a Y-connector.
Flow through the returning cannulae is balanced with an adjustable clamp and monitored with a separate flow sensor
on the upper return cannula.
Triple Cannulation ECMO
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VAV-ECMO N Description Outcomes
Madershahian et
al. 2007 [58]
1 3 pts. with VA-ECMO for ARDS and
polytrauma. In 1 pt., persistent upper body
hypoxemia on VA-ECMO, conversion to VAV 
Recovery, weaning from ECMO,
discharge
Stöhr et al. 2011
[60]
11 30 pts. with ARDS. Of these 18 with VV, 9 with
VA and 3 with primary VAV cannulation. 8
were upgraded from VV or VA to VAV, and 2
were switched from VV to VA. 11 pts. had
subclavian arterial cannulation
Bleeding in 8 pts., hyperperfusion/leg
ischemia/wound healing
complications in 1 pt. each. 15 pts.
died on ECMO, 1 pt. died after ECMO
removal. Mortality was higher in the
VV (63%) and the VA cohort (75%)
than in the VAV cohort (27%). Overall,
30-day mortality was 53%. 1 pt. was
bridged to lung transplantation.
During a mean follow-up of 21
months, 3 pts. died
Kustermann et al.
2013 [53]
1 30-year-old pt. with pneumonia, ARDS, and
severe septic cardiomyopathy. VA-ECMO was
expanded to VAV cannulation due to
persistently low Horovitz index on VA-ECMO
Recovery, weaning from ECMO and
invasive ventilation
Moravec et al. 2014
[55]
3 74-year-old pt. with pulmonary hypertension
and pulmonary fibrosis, pneumonia, sepsis, and
shock. VA-ECMO was expanded to VAV-ECMO
via a jugular Shaldon catheter for ARDS. 59-
year-old obese pt. with cardiogenic shock,
resuscitation during cardiac catheterization and
IABP. VA-ECMO was expanded to VAV-ECMO
via a jugular Shaldon catheter for ARDS. A third
pt. received VAV-ECMO with standard ECMO
cannulae.
Successful ECMO weaning in all
patients. Pt. 1 died from lung fibrosis,
pts. 2 and 3 survived with good
clinical result
Chung et al. 2014
[51]
Review Excellent review on monitoring during ECMO support includes a description of the
principle of VAV-ECMO
Choi et al. 2014
[49]
1 39-year old pt. with acute myocardial infarction.
VA-ECMO during resuscitation, after 5 days
secondary respiratory failure and upper-body
hypoxemia. Upgrade to VAV-ECMO
Successful ECMO and ventilator
weaning, rehabilitation, uneventful
recovery at 13 month follow-up
Kim et al. 2014
[57] 
1 9 pts. with ECMO after resuscitation for near-
drowning. 7 pts. with VA-ECMO, 1 was
converted to VV. 1 pt. patient initially received
VAV-ECMO
All pts. were successfully weaned
from ECMO, 7 pts. survived with a
favorable neurological outcome, 2 pts.
had irreversible hypoxic brain damage
and died. Outcome for the pt. with
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VAV-ECMO N Description Outcomes
VAV-ECMO is not specifically
provided.
Biscotti et al. 2014
[59]
21 21 pts. with VAV-ECMO. 11 with primary VAV,
8 with switching from VV to VAV, 1 had lung
transplantation on VA-ECMO and received
VAV-ECMO as a bridge to VV-ECMO. 1 had
ARDS and upper body hypoxemia on VA-
ECMO, which was subsequently expanded to
VAV
8 pts. died on ECMO, 4 were weaned
from ECMO but died before
discharge, 9 survived to discharge. 4
of 11 on primary VAV-ECMO
survived, 4 of 8 converted from VV to
VAV survived, 1 of 2 converted from
VA to VAV survived
Ius et al. 2015 [54] 10 9 pts. with VV- and 1 with VA-ECMO, for ARDS
or other forms of lung failure. All were switched
to VAV cannulation for new onset heart failure
(right heart failure, pericardial tamponade or
mitral regurgitation).
3 pts. were successfully bridged to
lung transplantation, 2 of which
survived to hospital discharge. 4 were
successfully weaned off ECMO, 3 of
which survived to discharge. 3 pts.
died on ECMO
Lee et al. 2016 [61] 1 27-year-old pt. with ARDS from concurrent
pneumonia and acute myocarditis. Primary
VAV-ECMO for ARDS and cardiogenic shock
Successful ECMO and ventilator
weaning, discharge
Jeon et al 2016 [62] 1 45-year old pt. with exacerbated asthma. VV-
ECMO for hypoxia despite mechanical
ventilation. Development of cardiogenic shock
from Takotsubo syndrome, switch to VAV-
ECMO, followed by reversion to VV-ECMO 3
days later
Successful ECMO and ventilator
weaning, rehabilitation, discharge
ELSO [5] Guideline The ELSO guideline for ECMO support in adults describes to convert VA to VAV
cannulation when severe respiratory failure occurs
pt, patient, pts, patients.
Table 4. Publications on VAV-ECMO support.
VAV cannulation is in most cases initiated as an “upgrade” from VV or VA-ECMO, either
when lung failure develops during heart failure on VA-ECMO or when heart failure develops
during lung failure on VV-ECMO. In the former situation, e.g., when pulmonary edema, severe
pneumonia, or ventilator-associated lung injury occur on VA-ECMO, myocardial and cerebral
oxygenation may be severely compromised. This is a result from the watershed phenomenon,
with cyanosis in the upper body and sufficient oxygenation in the lower body distal to the
watershed. This has also been termed differential hypoxia or “two-circulation syndrome” [49,
50]. Then a third cannula can be introduced for supplying preoxygenated blood to the lungs,
as such adding a VV-ECMO component to a running VA-ECMO.
Triple Cannulation ECMO
http://dx.doi.org/10.5772/63392
91
In the latter situation, preoxygenated blood enters the pulmonary circuit, since the patient is
already on VV-ECMO. However, when left-sided heart failure develops, e.g., by septic
cardiomyopathy or myocarditis, insufficient cardiac output will emerge as a major problem
irrespective of good oxygenation of venous blood [53, 54]. In this case, a third cannula can be
introduced to supply blood toward the aorta, with the intention to add a VA-ECMO
component to the running VV-ECMO. Until now, some case series and small observational
studies have demonstrated that VAV-ECMO may be used with well acceptable safety and
convincing efficacy [49, 53–62] (Table 4); however, prospective or controlled data are still
missing.
For VAV cannulation, usually the right jugular vein and the femoral vein and artery are used
as vascular access. The venous cannula tips should be positioned at the border between the
caval veins and the right atrium, comparable to VV-ECMO (Figures 5 and 1). VV-ECMO
running with a bicaval dual-lumen cannula may also be upgraded to VAV cannulation, with
the drainage lumen being connected to ECMO input and the return lumen to ECMO output.
In principle, ECMO outflow is divided using a Y-connector, for one cannula returning blood
toward the central aorta and one returning blood toward the right atrium (Figure 5). The flow
in both cannulae, which of course also depends on cannula diameters, is balanced by using an
adjustable clamp and monitored by a flow sensor (Figure 5). This is necessary, since the
demand of arterialized blood flow on each return cannula varies from patient to patient and
over time. Every change in flow balance will have an influence on preload, afterload, the
watershed position, and oxygen saturations at the same time. Modifications of oxygenator and
sweep gas settings will also influence oxygen saturation and carbon dioxide content in both
reinfusion cannulae at the same time. Therefore, during VAV-ECMO support, repetitive
echocardiography and continuous upper- and lower-body oxygenation surveillance are
mandatory to assess right and left ventricular filling and function, respectively as well as tissue
oxygenation. Respiratory support by VAV-cannulation is sufficient in most cases as it allows
for lung protective ventilation, but hemodynamic support is lower compared to VA or VVA
cannulation [54].
3.3. Veno-arterio-pulmonary-arterial cannulation (VAPa)
This is a special variant of VAV cannulation. It has not been validated in studies and is just
described here for the purpose of completeness. While VAV-ECMO combines the features of
VV and VA ECMO, VAPa ECMO intends to further support right heart failure during VAV-
ECMO. For this purpose, the returning venous cannula is forwarded through the tricuspid
valve, the right ventricle, and the pulmonary valve to the pulmonary artery (Figure 6). This
has to be performed under angiographic (or transesophageal echocardiographic) guidance,
and for this purpose a flexible 17 French cannula has to be used, as for VPa cannulation. The
smaller inner diameter of that cannula intrinsically influences the flow balance of both return
cannulae, which is further adjusted by a clamp and monitored by a flow sensor as with VAV-
ECMO. Similar to VA and VPa cannulation, the draining cannula tip should be positioned in
the mid right atrium to facilitate homogenous drainage of the upper and lower body.
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By VAPa-ECMO, the right heart is bypassed, and as such right-sided heart failure on VAV-
ECMO or left-sided heart failure on VPa-ECMO can be bridged but requires a competent
pulmonary valve. Again, it has to be noted that this type of ECMO is novel, as such experi‐
mental and has not been validated in clinical trials. An existing transfemoral venous ECMO
cannulation does not allow for additional implantation of a microaxial right heart-assist device
(Impella RP®, Abiomed). Thus, the combination of VA-ECMO and Impella RP® is not an
option, and in contrast to VPa-ECMO, this approach would not offer oxygenation and
decarboxylation of pulmonary blood.
Figure 6. Veno-arterio-pulmonary arterial ECMO (VAPa). VAPa-ECMO drains venous blood (blue) from the right at‐
rium and returns balanced volumes blood after reoxygenation and decarboxylation (red) to the iliac artery toward the
aorta and to the pulmonary artery. For this purpose, the ECMO outflow is divided by a Y-connector. Flow through the
returning cannulae is balanced with an adjustable clamp and monitored with a separate flow sensor on the upper re‐
turn cannula.
4. Summary
VV and VA cannulation are the most common configurations of percutaneous ECMO support,
serving to bridge severe respiratory and cardiac failure, respectively. VPa cannulation is a
novel modification of VV ECMO to support respiratory failure complicated by right heart
failure. Recently, triple cannulation ECMO has been introduced, either VVA cannulation for
improved drainage or VAV cannulation for combined lung and heart failure. VAV may further
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be modified to VAPa cannulation, mainly for severe right heart failure during VAV-ECMO.
Novel and triple cannulations expand the spectrum of ECMO in special clinical situations;
however, such configurations are even more complex than standard ECMO and require most
intense monitoring and awareness. Notwithstanding these promising developments, we need
prospective controlled trials of standard and advanced ECMO configurations to unequivocally
assess safety and efficacy and to identify predictors of initiation and weaning of mechanical
support.
Conflict of interest LCN and JB report no conflicts of interest related to this work.
Author details
L. Christian Napp* and Johann Bauersachs
*Address all correspondence to: napp.christian@mh-hannover.de
Cardiac Arrest Center, Department of Cardiology and Angiology, Hannover Medical School,
Hannover, Germany
References
[1] Hill JD, O’Brien TG, Murray JJ, Dontigny L, Bramson ML, Osborn JJ, et al. Prolonged
extracorporeal oxygenation for acute post-traumatic respiratory failure (shock-lung
syndrome). Use of the Bramson membrane lung. N Engl J Med. 1972;286(12):629–34.
[2] Thiele H, Zeymer U, Neumann FJ, Ferenc M, Olbrich HG, Hausleiter J, et al. Intraaortic
balloon support for myocardial infarction with cardiogenic shock. N Engl J Med.
2012;367(14):1287–96.
[3] Zeymer U, Hochadel M, Hauptmann KE, Wiegand K, Schuhmacher B, Brachmann J,
et al. Intra-aortic balloon pump in patients with acute myocardial infarction compli‐
cated by cardiogenic shock: results of the ALKK-PCI registry. Clinical Res Cardiol.
2013;102(3):223–7.
[4] Zangrillo A, Landoni G, Biondi-Zoccai G, Greco M, Greco T, Frati G, et al. A meta-
analysis of complications and mortality of extracorporeal membrane oxygenation. Crit
Care Resusc. 2013;15(3):172–8.
[5] Extracorporeal Life Support Organization: ELSO guidelines. Available from: http://
www.elso.org/resources/guidelines. Access Date: 27.08.2014.
[6] Napp LC, Kühn C, Hoeper MM, Vogel-Claussen J, Haverich A, Schäfer A, Bauersachs
J. Cannulation strategies for percutaneous extracorporeal membrane oxygenation in
adults. Clin Res Cardiol. 2016 Apr;105(4):283-96.
Extracorporeal Membrane Oxygenation: Advances in Therapy94
[7] Werdan K, Gielen S, Ebelt H, Hochman JS. Mechanical circulatory support in cardio‐
genic shock. Eur Heart J. 2014;35(3):156–67.
[8] Ferrari M, Kruzliak P, Spiliopoulos K. An insight into short- and long-term mechanical
circulatory support systems. Clin Res Cardiol. 2015;104(2):95–111.
[9] Brodie D, Bacchetta M. Extracorporeal membrane oxygenation for ARDS in adults. N
Engl J Med. 2011;365(20):1905–14.
[10] Morris AH, Wallace CJ, Menlove RL, Clemmer TP, Orme JF, Jr., Weaver LK, et al.
Randomized clinical trial of pressure-controlled inverse ratio ventilation and extrac‐
orporeal CO2 removal for adult respiratory distress syndrome. Am J Respir Crit Care
Med. 1994;149(2 Pt 1):295–305.
[11] Peek GJ, Mugford M, Tiruvoipati R, Wilson A, Allen E, Thalanany MM, et al. Efficacy
and economic assessment of conventional ventilatory support versus extracorporeal
membrane oxygenation for severe adult respiratory failure (CESAR): a multicentre
randomised controlled trial. Lancet. 2009;374(9698):1351–63.
[12] Sidebotham D. Extracorporeal membrane oxygenation--understanding the evidence:
CESAR and beyond. J Extra-corpor Technol. 2011;43(1):P23–6.
[13] Zapol WM, Snider MT, Hill JD, Fallat RJ, Bartlett RH, Edmunds LH, et al. Extracor‐
poreal membrane oxygenation in severe acute respiratory failure. A randomized
prospective study. JAMA. 1979;242(20):2193–6.
[14] Brogan TV, Thiagarajan RR, Rycus PT, Bartlett RH, Bratton SL. Extracorporeal mem‐
brane oxygenation in adults with severe respiratory failure: a multi-center database.
Intensiv Care Med. 2009;35(12):2105–14.
[15] Fuehner T, Kuehn C, Hadem J, Wiesner O, Gottlieb J, Tudorache I, et al. Extracorporeal
membrane oxygenation in awake patients as bridge to lung transplantation. Am J
Respir Crit Care Med. 2012;185(7):763–8.
[16] Wiesner O, Hadem J, Sommer W, Kuhn C, Welte T, Hoeper MM. Extracorporeal
membrane oxygenation in a nonintubated patient with acute respiratory distress
syndrome. Eur Respir J. 2012;40(5):1296–8.
[17] Schmidt F, Sasse M, Boehne M, Mueller C, Bertram H, Kuehn C, et al. Concept of “awake
venovenous extracorporeal membrane oxygenation” in pediatric patients awaiting
lung transplantation. Pediatr Transplant. 2013;17(3):224–30.
[18] Hoeper MM, Wiesner O, Hadem J, Wahl O, Suhling H, Duesberg C, et al. Extracorporeal
membrane oxygenation instead of invasive mechanical ventilation in patients with
acute respiratory distress syndrome. Intensiv Care Med. 2013;39(11):2056–7.
[19] Pham T, Combes A, Roze H, Chevret S, Mercat A, Roch A, et al. Extracorporeal
membrane oxygenation for pandemic influenza A(H1N1)-induced acute respiratory
Triple Cannulation ECMO
http://dx.doi.org/10.5772/63392
95
distress syndrome: a cohort study and propensity-matched analysis. Am J Respir Crit
Care Med. 2013;187(3):276–85.
[20] Australia, New Zealand Extracorporeal Membrane Oxygenation Influenza I, Davies A,
Jones D, Bailey M, Beca J, et al. Extracorporeal membrane oxygenation for 2009
influenza A(H1N1) acute respiratory distress syndrome. JAMA. 2009;302(17):1888–95.
[21] Kumar A, Zarychanski R, Pinto R, Cook DJ, Marshall J, Lacroix J, et al. Critically ill
patients with 2009 influenza A(H1N1) infection in Canada. JAMA. 2009;302(17):1872–
9.
[22] Beutel G, Wiesner O, Eder M, Hafer C, Schneider AS, Kielstein JT, et al. Virus-associated
hemophagocytic syndrome as a major contributor to death in patients with 2009
influenza A (H1N1) infection. Crit Care. 2011;15(2):R80.
[23] Bermudez CA, Rocha RV, Sappington PL, Toyoda Y, Murray HN, Boujoukos AJ. Initial
experience with single cannulation for venovenous extracorporeal oxygenation in
adults. Ann Thorac Surg. 2010;90(3):991–5.
[24] Anderson MB, Goldstein J, Milano C, Morris LD, Kormos RL, Bhama J, et al. Benefits
of a novel percutaneous ventricular assist device for right heart failure: the prospective
RECOVER RIGHT study of the Impella RP device. J Heart Lung Transplant.
2015;34(12):1549–60.
[25] McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, et al. ESC
guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the
task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the
European Society of Cardiology. Developed in collaboration with the Heart Failure
Association (HFA) of the ESC. Eur Heart J. 2012;33(14):1787–847.
[26] Maxwell BG, Powers AJ, Sheikh AY, Lee PH, Lobato RL, Wong JK. Resource use trends
in extracorporeal membrane oxygenation in adults: an analysis of the Nationwide
Inpatient Sample 1998–2009. J Thorac Cardiovasc Surg. 2014;148(2):416–21 e1.
[27] Sheu JJ, Tsai TH, Lee FY, Fang HY, Sun CK, Leu S, et al. Early extracorporeal membrane
oxygenator-assisted primary percutaneous coronary intervention improved 30-day
clinical outcomes in patients with ST-segment elevation myocardial infarction compli‐
cated with profound cardiogenic shock. Crit Care Med. 2010;38(9):1810–7.
[28] Guenther S, Theiss HD, Fischer M, Sattler S, Peterss S, Born F, et al. Percutaneous
extracorporeal life support for patients in therapy refractory cardiogenic shock: initial
results of an interdisciplinary team. Interact Cardiovasc Thorac Surg. 2014;18(3):283–
91.
[29] Asaumi Y, Yasuda S, Morii I, Kakuchi H, Otsuka Y, Kawamura A, et al. Favourable
clinical outcome in patients with cardiogenic shock due to fulminant myocarditis
supported by percutaneous extracorporeal membrane oxygenation. Eur Heart J.
2005;26(20):2185–92.
Extracorporeal Membrane Oxygenation: Advances in Therapy96
[30] Lorusso R, Centofanti P, Gelsomino S, Barili F, Di Mauro M, Orlando P, et al. Venoar‐
terial extracorporeal membrane oxygenation for acute fulminant myocarditis in adult
patients: a 5-year multi-institutional experience. Ann Thorac Surg. 2016;101(3):919–26.
[31] Hoeper MM, Tudorache I, Kuhn C, Marsch G, Hartung D, Wiesner O, et al. Extracor‐
poreal membrane oxygenation watershed. Circulation. 2014;130(10):864–5.
[32] Belohlavek J, Rohn V, Jansa P, Tosovsky J, Kunstyr J, Semrad M, et al. Veno-arterial
ECMO in severe acute right ventricular failure with pulmonary obstructive hemody‐
namic pattern. J Invasive Cardiol. 2010;22(8):365–9.
[33] Sommer W, Marsch G, Kaufeld T, Rontgen P, Beutel G, Tongers J, et al. Cardiac awake
extracorporeal life support-bridge to decision? Artif Organs. 2015;39(5):400–8.
[34] Olsson KM, Simon A, Strueber M, Hadem J, Wiesner O, Gottlieb J, et al. Extracorporeal
membrane oxygenation in nonintubated patients as bridge to lung transplantation. Am
J Transplant. 2010;10(9):2173–8.
[35] Javidfar J, Brodie D, Takayama H, Mongero L, Zwischenberger J, Sonett J, et al. Safe
transport of critically ill adult patients on extracorporeal membrane oxygenation
support to a regional extracorporeal membrane oxygenation center. ASAIO J.
2011;57(5):421–5.
[36] Spina R, Forrest AP, Adams MR, Wilson MK, Ng MK, Vallely MP. Veno-arterial
extracorporeal membrane oxygenation for high-risk cardiac catheterisation proce‐
dures. Heart Lung Circ. 2010;19(12):736–41.
[37] Iliodromitis KE, Kahlert P, Plicht B, Hoffmann AC, Eggebrecht H, Erbel R, et al. High-
risk PCI in acute coronary syndromes with Impella LP 2.5 device support. Int J Cardiol.
2011;153(1):59–63.
[38] Haneya A, Philipp A, Puehler T, Ried M, Hilker M, Zink W, et al. Ventricular assist
device implantation in patients on percutaneous extracorporeal life support without
switching to conventional cardiopulmonary bypass system. Eur J Cardio-thorac Surg.
2012;41(6):1366–70.
[39] Rousse N, Juthier F, Pincon C, Hysi I, Banfi C, Robin E, et al. ECMO as a bridge to
decision: recovery, VAD, or heart transplantation? Int J Cardiol. 2015;187:620–7.
[40] Tudorache I, Sommer W, Kuhn C, Wiesner O, Hadem J, Fuhner T, et al. Lung trans‐
plantation for severe pulmonary hypertension—awake extracorporeal membrane
oxygenation for postoperative left ventricular remodelling. Transplantation.
2015;99(2):451–8.
[41] Jaski BE, Ortiz B, Alla KR, Smith SC, Jr., Glaser D, Walsh C, et al. A 20-year experience
with urgent percutaneous cardiopulmonary bypass for salvage of potential survivors
of refractory cardiovascular collapse. J Thorac Cardiovasc Surg. 2010;139(3):753–7 e1–
2.
Triple Cannulation ECMO
http://dx.doi.org/10.5772/63392
97
[42] Jung C, Janssen K, Kaluza M, Fuernau G, Poerner TC, Fritzenwanger M, Pfeifer R,
Thiele H, Figulla HR. Outcome predictors in cardiopulmonary resuscitation facilitated
by extracorporeal membrane oxygenation. Clin Res Cardiol. 2016 Mar;105(3):196-205.
[43] Kagawa E, Dote K, Kato M, Sasaki S, Nakano Y, Kajikawa M, et al. Should we emer‐
gently revascularize occluded coronaries for cardiac arrest? Rapid-response extracor‐
poreal membrane oxygenation and intra-arrest percutaneous coronary intervention.
Circulation. 2012;126(13):1605–13.
[44] Napp LC, Brehm M, Kuhn C, Schafer A, Bauersachs J. Heart against veno-arterial
ECMO: competition visualized. Int J Cardiol. 2015;187:164–5.
[45] Bisdas T, Beutel G, Warnecke G, Hoeper MM, Kuehn C, Haverich A, et al. Vascular
complications in patients undergoing femoral cannulation for extracorporeal mem‐
brane oxygenation support. Ann Thorac Surg. 2011;92(2):626–31.
[46] Cheng A, Swartz MF, Massey HT. Impella to unload the left ventricle during peripheral
extracorporeal membrane oxygenation. ASAIO J. 2013;59(5):533–6.
[47] Chaparro SV, Badheka A, Marzouka GR, Tanawuttiwat T, Ahmed F, Sacher V, et al.
Combined use of Impella left ventricular assist device and extracorporeal membrane
oxygenation as a bridge to recovery in fulminant myocarditis. ASAIO J. 2012;58(3):285–
7.
[48] Koeckert MS, Jorde UP, Naka Y, Moses JW, Takayama H. Impella LP 2.5 for left
ventricular unloading during venoarterial extracorporeal membrane oxygenation
support. J Card Surg. 2011;26(6):666–8.
[49] Choi JH, Kim SW, Kim YU, Kim SY, Kim KS, Joo SJ, et al. Application of veno-arterial-
venous extracorporeal membrane oxygenation in differential hypoxia. Multidisciplin
Respir Med. 2014;9(1):55.
[50] Hou X, Yang X, Du Z, Xing J, Li H, Jiang C, et al. Superior vena cava drainage improves
upper body oxygenation during veno-arterial extracorporeal membrane oxygenation
in sheep. Crit Care. 2015;19:68.
[51] Chung M, Shiloh AL, Carlese A. Monitoring of the adult patient on venoarterial
extracorporeal membrane oxygenation. Sci World Jour. 2014;2014:393258.
[52] Ford EG, Atkinson JB. Augmented venous access in the problematic ECMO patient: a
case report. J Pediatr Surg. 1992;27(4):527–8.
[53] Kustermann J, Gehrmann A, Kredel M, Wurmb T, Roewer N, Muellenbach RM. [Acute
respiratory distress syndrome and septic cardiomyopathy: successful application of
veno-venoarterial extracorporeal membrane oxygenation]. Der Anaesthesist.
2013;62(8):639–43.
[54] Ius F, Sommer W, Tudorache I, Avsar M, Siemeni T, Salman J, et al. Veno-veno-arterial
extracorporeal membrane oxygenation for respiratory failure with severe haemody‐
Extracorporeal Membrane Oxygenation: Advances in Therapy98
namic impairment: technique and early outcomes. Interact Cardiovasc Thorac Surg.
2015;20(6):761–7.
[55] Moravec R, Neitzel T, Stiller M, Hofmann B, Metz D, Bucher M, et al. First experiences
with a combined usage of veno-arterial and veno-venous ECMO in therapy-refractory
cardiogenic shock patients with cerebral hypoxemia. Perfusion. 2014;29(3):200–9.
[56] Chung JC, Tsai PR, Chou NK, Chi NH, Wang SS, Ko WJ. Extracorporeal membrane
oxygenation bridge to adult heart transplantation. Clin Transplant. 2010;24(3):375–80.
[57] Kim KI, Lee WY, Kim HS, Jeong JH, Ko HH. Extracorporeal membrane oxygenation in
near-drowning patients with cardiac or pulmonary failure. Scand J Trauma Resusc
Emerg Med. 2014;22:77.
[58] Madershahian N, Wittwer T, Strauch J, Franke UF, Wippermann J, Kaluza M, et al.
Application of ECMO in multitrauma patients with ARDS as rescue therapy. J Card
Surg. 2007;22(3):180–4.
[59] Biscotti M, Lee A, Basner RC, Agerstrand C, Abrams D, Brodie D, et al. Hybrid
configurations via percutaneous access for extracorporeal membrane oxygenation: a
single-center experience. ASAIO J. 2014;60(6):635–42.
[60] Stohr F, Emmert MY, Lachat ML, Stocker R, Maggiorini M, Falk V, et al. Extracorporeal
membrane oxygenation for acute respiratory distress syndrome: is the configuration
mode an important predictor for the outcome? Interact Cardiovasc Thorac Surg.
2011;12(5):676–80.
[61] Lee JH, Park JH, Min HK, Seo GW, Song PS, Her C, et al. Veno-veno-arterial ECMO
support for acute myocarditis combined with ARDS: a case report. Int J Artif Organs.
2016;38(12):667–70.
[62] Jeon YJ, Byun JH, Hwang SW, Park JH, Lee JH. Successful application of veno-
venoarterial extracorporeal membrane oxygenation for acute exacerbation of asthma
followed by stress cardiomyopathy. Yonsei Med J. 2016;57(2):536–7.
Triple Cannulation ECMO
http://dx.doi.org/10.5772/63392
99

